MedTrace Logo

Accelerating COVID-19 Clinical Recovery in the Outpatient Setting: Retrospective Analysis

NCT05520944 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2022-08-30

No results posted yet for this study

Summary

The purpose of this retrospective study is to evaluate the effectiveness of CPM nasal spray as part of the treatment of COVID-19 and its impact on clinical symptoms. Two cohort groups will be compared (CPM vs. standard care). The hypothesis to be tested is that patients treated with CPM nasal spray showed more rapid clinical improvement than those treated with standard of care alone. Clinical improvement will be evaluated by the total number of days with the manifestation of COVID-19 symptoms, including cough, nasal congestion, ageusia, and anosmia, among others. The rate of hospitalization between the cohorts will also be evaluated.

Conditions

  • COVID-19
  • COVID-19 Pandemic
  • COVID-19 Respiratory Infection
  • SARS CoV 2 Infection
  • SARS-CoV-2 Acute Respiratory Disease

Interventions

DRUG

ClorNovir® (Chlorpheniramine) 0.4% Nasal Spray

Patients will have received treatment with ClorNovir® as prescribed by their physician at the approved dose per local prescribing information, as part of their COVID-19 clinical recovery.

Sponsors & Collaborators

  • Clinica Union Medica Del Norte, S.A.S., Santiago, República Dominicana

    collaborator UNKNOWN

  • Dr. Ferrer BioPharma

    lead INDUSTRY

Eligibility

Min Age
6 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-26
Primary Completion
2022-09-30
Completion
2022-10-01
FDA Drug
Yes

Countries

  • Dominican Republic

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05520944 on ClinicalTrials.gov